RAF1 is increased in labouring myometrium and modulates inflammation-induced pro-labour mediators

Martha Lappas¹,²

¹Mercy Perinatal Research Centre, Mercy Hospital for Women, Heidelberg, Victoria, Australia and ²Obstetrics, Nutrition and Endocrinology Group, Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Level 4/163 Studley Road, Heidelberg 3084, Victoria, Australia

Correspondence should be addressed to M Lappas; Email: mlappas@unimelb.edu.au

Abstract

Inflammation plays a central role in the terminal process of human labour and delivery, including myometrial contractions. RAF1 proto-oncogene serine/threonine-protein kinase (RAF1) can activate ERK (official gene symbol MAPK1) and/or nuclear factor-kappa B (NF-κB) to regulate genes involved in inflammation. There are, however, no studies on the role of RAF1 in the processes of human labour and delivery. Thus, the aims of this study were to determine the effect of i) human labour and pro-inflammatory cytokines interleukin 1 beta (IL1B) and tumour necrosis factor (TNF) alpha on RAF1 protein expression in myometrium and ii) siRNA knockdown of RAF1 on pro-inflammatory and pro-labour mediators in human myometrial primary cells. Term labour was associated with an increase in RAF1 protein expression. Furthermore, RAF1 protein expression was increased in myometrial cells treated with IL1B and TNF, two likely factors contributing to preterm birth. Knockdown of RAF1 by siRNA in primary myometrial cells significantly decreased IL1B- and TNF-induced IL1A, IL1B, IL6, (C-X-C motif) ligand 8 (CXCL8) and chemokine (C-C motif) ligand 2 (CCL2) mRNA levels and prostaglandin PGF2α release; and NF-κB activation. Furthermore, RAF1 knockdown was associated with decreased activation of ERK in the presence of IL1B but not TNF. Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2α release; and NF-κB activation. In conclusion, IL1B induces the expression and secretion of pro-labour mediators through the RAF1–MAPK1–NF-κB signalling pathway. TNF, on the other hand, regulates pro-labour mediators through the RAF1–NF-κB signalling pathway via an MAPK1-independent mechanism.

Reproduction (2016) 151 411–420

Introduction

Preterm birth is the biggest cause of neonatal morbidity and mortality (Blencowe et al. 2013). Currently, there are no effective strategies to prevent preterm birth due to an incomplete understanding of the underlying mechanisms involved in human labour and delivery. What we do know is that inflammation is central to both human term and preterm labour (Christiaens et al. 2008, Shynlova et al. 2013), with an influx of inflammatory cells into the uterus (Thomson et al. 1999, Osman et al. 2003). Cytokines, such as interleukin 1 beta (IL1B) and tumour necrosis factor (TNF) alpha, released by leukocytes, promote the synthesis of prostaglandin-endoperoxide synthase 2 (PTGS2)-dependent prostaglandins which are important regulators of myometrial contractility (Bartlett et al. 1999, Erkinheimo et al. 2000, Rauk & Chiao 2000).

RAF1 proto-oncogene serine/threonine-protein kinase, also known as cRaf or RAF1, is a member of the Raf kinase family of serine/threonine-specific protein kinases that also consists of A-Raf and B-Raf. RAF1 is principle component of the ERK (official gene symbol MAPK1) pathway; it acts as a MAP kinase kinase kinase (MAP3K) initiating the entire kinase cascade. Once activated, RAF1 can phosphorylate to activate the dual-specific MAP kinase/ERK kinase 1 (MEK1) and MEK2, which in turn phosphorylate to activate the serine/threonine-specific protein kinases ERK1 and ERK2 (Alessi et al. 1994). Pleiotropic functions of activated MAPK1 include regulation of genes involved in the cell division cycle, apoptosis, cell differentiation and cell migration (Meloche & Pouyssegur 2007, Mebratu & Tesfaigzi 2009, Roskoski 2012). ERK can also activate many transcription regulators, including nuclear factor-kappa B (NF-κB) (Nakano et al. 1998, Lu et al. 2010). Notably, many other non-MEK/MAPK1-mediated functions of RAF1 have been postulated (Chen et al. 2001, Ehrenreiter et al. 2005, 2009), including regulation of NF-κB signalling (Baumann et al. 2000, Edelblum et al. 2008a,b).

NF-κB is a pro-inflammatory transcription factor that plays a central role in the regulation of the genes
involved in the terminal effector pathways of human labour and delivery (Lappas et al. 2002, 2003, Lindstrom & Bennett 2005, Lappas & Rice 2007). In human myometrium, IL1B and TNF can induce NF-κB activation to induce the expression of pro-inflammatory cytokines and PTGS2 (Khanjani et al. 2012, Liong & Lappas 2015). Similarly, emerging evidence suggests that MAPK1 also regulates pro-labour mediators in human gestational tissues. In human placenta and foetal membranes, inhibition of MAPK1 using U0126 is associated with decreased lipopolysaccharide (LPS)- or IL1B-induced pro-inflammatory cytokines (Lappas et al. 2007) and matrix degrading enzymes (Lappas et al. 2011), while in human myometrium, MAPK1 is activated during contractions (Paul et al. 2011). In non-gestational tissues, there is ample evidence that RAF1 regulates inflammation. For example, in RAW 264.7 mouse macrophages, inhibition of RAF1 blocks LPS-induced TNF mRNA expression, while overexpression of RAF1 augments LPS-induced TNF mRNA expression (Geppert et al. 1994). Similarly, adenovirus infection stimulates the Raf/MAPK1 signalling pathway and induces chemokine (C-X-C motif) ligand 8 (CXCL8) expression in HeLa cells (Bruder & Kovesdi 1997). There are, however, no studies on RAF1 in myometrium and its role in regulating inflammation.

Thus, the hypothesis to be tested is that RAF1 expression is increased in myometrium with human labour and mediators of preterm labour, and inhibition of RAF1 is associated with decreased expression of pro-inflammatory and pro-labour mediators. The aims of this study were to determine i) the effect of human term spontaneous labour and pro-inflammatory cytokines on RAF1 expression in human myometrium, ii) the effect of RAF1 siRNA knockdown on inflammation-induced pro-labour mediators in primary cells isolated from human myometrium and iii) if RAF1 regulates pro-labour mediators via ERK- and/or NF-κB-dependent mechanisms.

Materials and methods

Tissue collection

The Research Ethics Committee of Mercy Hospital for Women approved this study. Written, informed consent was obtained from all participating women. All tissues were obtained from women who delivered healthy, singleton infants at term (37–41 weeks gestation) undergoing elective caesarean section in the absence of labour. Cells were isolated and cultured, as described previously (Lim et al. 2013). Briefly, myometrium was minced and digested for 1 h in DMEM/Nutrient Mixture F12 Ham (DMEM/F12) with 3 mg/ml type I collagenase (Worthington Biochemical, Freehold, NJ, USA) and 80 μg/ml DNase 1 (Roche Diagnostics) at 37 °C. Cells were centrifuged at 400 g for 10 min and grown in DMEM/F12 enriched with 10% heat-inactivated FCS (containing 100 U/ml penicillin G and 100 mg/ml streptomycin).

To determine the effect of pro-inflammatory cytokines on RAF1 expression and the ERK inhibitor U0126 (MAPK1 inhibitor) on the expression of pro-labour mediators, women who delivered healthy, singleton infants at term (37–41 weeks gestation) undergoing elective caesarean section in the absence of labour. Cells were isolated and cultured, as described previously (Lim et al. 2013). Briefly, myometrium was minced and digested for 1 h in DMEM/Nutrient Mixture F12 Ham (DMEM/F12) with 3 mg/ml type I collagenase (Worthington Biochemical, Freehold, NJ, USA) or 10 ng/ml TNF (PeproTech) with or without 5 μM U0126 (Tocris, Minneapolis, MN, USA) for 20 h. The concentrations of IL1B and TNF are based on previous studies in myometrial cells (Liong & Lappas 2015). Cells were collected and stored at −80 °C until assayed for mRNA expression by qRT-PCR. Media was collected and stored at −80 °C until assayed for cytokine and prostaglandin release, as detailed below. Experiments were performed from myometrium obtained from five patients.

For the siRAFI studies, transfection of primary myometrial cells was performed, as we have previously described (Lappas 2015). Briefly, cells at ~80% confluence were transfection using Lipofectamine 3000, according to manufacturer’s guidelines (Life Technologies). siRAFI and negative control siRNA (siCONT) was obtained from OriGene (Rockville, MD, USA). Cells were transfected with 200 nM siRAFI or 200 nM siCONT in DMEM/F12 for 48 h. The medium was then replaced with fresh media in the absence of siRNA. Treatment was performed in the absence or presence of 5 μM U0126 (Tocris, Minneapolis, MN, USA) for 20 h. The concentrations of IL1B and TNF are based on previous studies in myometrial cells (Liong & Lappas 2015). Cells were collected and stored at −80 °C until assayed for mRNA expression by qRT-PCR. Media was collected and stored at −80 °C until assayed for cytokine and prostaglandin release, as detailed below. Experiments were performed from myometrium obtained from five patients.
replaced with DMEM/F12 (containing 0.5% BSA) with or without 1 ng/ml IL1B or 10 ng/ml TNF, and the cells were incubated at 37 °C for an additional 20 h. Cells were collected and stored at −80 °C until assayed for mRNA expression by qRT-PCR and protein expression by western blotting, as detailed below. Media was collected and stored at −80 °C until assayed for cytokine and prostaglandin release, as detailed below. Cell viability was assessed by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) proliferation assay, as we have previously described (Lim et al. 2014). The response to IL1B and TNF between patients varied greatly, as we have previously reported (Lappas 2015). Thus, data are presented as fold change in expression relative to the expression level in the IL1B- or TNF-stimulated siCONT-transfected cells, which was set at one. Data could not be normalised to siCONT-transfected cells alone, as some of the readings were zero. Experiments were performed from myometrium obtained from five patients.

**NF-κB luciferase assay**

A luciferase assay was utilised to determine possible interactions between RAF1 and NF-κB, as described previously (Lim et al. 2016). Primary myometrial cells, prepared as described above, at ∼70% confluence, were transfected with 0.75 ng NF-κB reporter construct (Qiagen, Chadstone Centre) using FuGENE HD transfection reagent (Promega). After 6 h, cells were transfected with 200 nM of siRAF1 or siCONT (as detailed above) for 48 h. The medium was then replaced with DMEM/F12 (containing 0.5% BSA), with or without 1 ng/ml IL1B or 10 ng/ml TNF, and the cells incubated at 37 °C for an additional 20 h.

To determine the effect of U0126 on NF-κB activity, primary myometrial cells were transfected with 0.75 ng NF-κB reporter construct, as detailed above. After 48 h incubation, cells were treated with 1 ng/ml IL1B in the absence or presence of 5 μM U0126 and the cells incubated at 37 °C for an additional 20 h.

After final incubation, cells were harvested in lysis buffer, and luminescence activity was measured using a Luciferase Reporter Assay kit (Life Research, Scoresby, Australia) and Renilla Luciferase Flash Assay kit (Promega) as instructed. The ratio of the firefly luciferase level to the Renilla luciferase level was determined, and the results are expressed as a ratio of normalised luciferase activity. The experiments were performed from myometrium obtained from five patients.

**Immunohistochemistry**

To determine the expression of RAF1 in myometrium, IHC was performed on paraffin sections, as described previously (Lappas 2015) using the IHC Select HRP Detection Set (Merck Millipore). Briefly, sections were deparaffinised followed by an antigen retrieval step (boiled in 10 mM Tris, 1 mM EDTA, pH 9.0 for 10 min, followed by 20 min incubation) and then endogenous peroxidases were inactivated by adding 3% hydrogen peroxide for 10 min. After blocking (Blocking Reagent: normal goat serum in PBS) for 5 min, sections were incubated with 1 μg/ml rabbit polyclonal anti-RAF1 (GTX107763; GeneTex, CA, USA) in 1% (wt/vol) BSA in PBS and incubated in a humidity chamber at 4 °C overnight. Binding sites were labelled with biotin-conjugated rabbit anti-goat IgG antibody followed by the streptavidin–HRP. Negative control slides, where primary antibody was replaced with rabbit IgG, were also performed.

**RNA extraction and qRT-PCR**

RNA extraction and qRT-PCR was performed, as described previously (Lim et al. 2016). Briefly, total RNA was extracted from cells using TRIzol reagent, according to the manufacturer’s instructions (Bioline; Alexandria, Australia). RNA concentration and purity were measured using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific; Scoresby, Australia). RNA (0.2 μg) was converted to cDNA using the Tetro cDNA Synthesis kit (Bioline), according to the manufacturer’s instructions. The RT-PCR was performed using the CFX384 real-time PCR detection system (Bio-Rad Laboratories) using 100 nM of pre-designed and validated QuantiTect primers (Qiagen). Average gene Ct values were normalised against two housekeeping genes (beta-2-microglobulin (B2M) and succinate dehydrogenase complex flavoprotein subunit A (SDHA)). Of note, there was no effect of experimental treatment on B2M or SDHA mRNA expression. Fold differences were determined using the comparative Ct method.

**Western blotting**

Western blotting was performed, as described previously (Lim et al. 2016). Blots were incubated in 1 μg/ml rabbit polyclonal anti-RAF1 (GTX107763; GeneTex, CA, USA), 1 μg/ml rabbit polyclonal anti-MAPK1 (sc-93; Santa Cruz Biotechnology) or 1 μg/ml mouse monoclonal anti-phosphorylated MAPK1 (sc-7383; Santa Cruz Biotechnology) prepared in blocking buffer (5% skim milk in TBS with 0.05% Tween-20) for 16 h at 4 °C. Membranes were viewed and analysed using the ChemiDoc XRS system (Bio-Rad Laboratories). Semi-quantitative analysis of the relative density of the bands in western blots was performed using Quantity One 4.2.1 Image Analysis Software (Bio-Rad Laboratories). For the labour studies, RAF1 protein expression was normalised to Ponceau S stain, as described previously (Lim et al. 2016); a section of the Ponceau S stained membrane was chosen which did not show variation with labour status.

**Cytokine and prostaglandin assays**

The release of IL6, CXCL8 and chemokine (C-C motif) ligand 2 (CCL2) was performed using CytoSet sandwich ELISA, according to the manufacturer’s instructions (Life Technologies). The limit of detection of the IL6, CXCL8 and CCL2 assays was 16, 12 and 15 pg/ml respectively. The release of PGF2α into the incubation medium was assayed using a commercially available competitive enzyme immunoassay kit, according to the manufacturer’s specifications (Kookaburra Kits from Sapphire Bioscience, Redfern, NSW, Australia). The limit of detection of the PGF2α assay was 60 pg/ml. For all assays, the inter- and intra-assay coefficients of variation were <10%.
Statistical analysis

Statistics was performed on the normalised data unless otherwise specified. All statistical analyses were undertaken using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). For Fig. 1B, an unpaired Student’s t-test was used to assess statistical significance between normally distributed data; otherwise, the non-parametric Mann–Whitney U was used. For Fig. 1C, one sample t-test, against the constant of one, was used. For Figs 2, 3, 4, 5 and 6, the homogeneity of data was assessed by Bartlett’s test, and when significant, the data were logarithmically transformed before further analysis. The data were analysed by one-way ANOVA using Fisher’s least significant difference post hoc test to allow multiple comparisons between groups. Statistical significance was ascribed to P value <0.05. Data were expressed as mean±S.E.M., unless otherwise specified.

Results

Effect term labour on RAF1 expression in human myometrium

To determine the effect of spontaneous term labour on RAF1 expression, myometrium was obtained from women at term caesarean section in the absence of labour (term no labour; n=8 patients) and after spontaneous labour onset (term in labour; n=8 patients). IHC revealed that RAF1 staining was present in the longitudinal and transverse muscle fibres (Fig. 1A); staining of RAF1 was more intense in the labouring group. No non-specific staining was present in the negative control. RAF1 protein expression, as analysed by western blotting, was also significantly higher in

Figure 1 Effect of human labour and pro-inflammatory cytokines on RAF1 expression in myometrium. (A and B) Human myometrium was obtained from non-labouring and labouring women at term caesarean section (n=8 patients/group). (A) immunohistochemical expression of RAF1. These sections are representative of one patient sample per group. Negative control is also displayed; original magnification ×100. (B) RAF1 protein expression was analysed by western blotting and Ponceau S stain was used as a loading control. The fold change was calculated relative to basal. All data are displayed as mean±S.E.M.*P<0.05 vs no labour (Student’s t-test). Representative western blot from three patients per group is also shown. (C) Human primary myometrial cells were incubated in the absence or presence of 1 ng/ml IL1B or 10 ng/ml TNF for 20 h (n=4 patients). RAF1 protein expression was analysed by western blot. Protein expression was normalised to ACTB, and the fold change was calculated relative to basal. All data are displayed as mean±S.E.M.*P<0.05 vs basal (one sample t-test). Representative western blot from one patient is also shown.

Figure 2 Effect of siRAF1 knockdown on IL1B-induced pro-inflammatory cytokines and chemokines. Human primary myometrial cells were transfected with or without 200 nM siRAF1 or siCONT for 48 h and then treated with 1 ng/ml IL1B for an additional 20 h (n=8 patients). (A, B and C) IL6, CXCL8 and CCL2 mRNA abundance was analysed by qRT-PCR, and the fold change was calculated relative to IL1B-stimulated siCONT-transfected cells. (D, E and F) IL6, CXCL8 and CCL2 concentration in the incubation medium was assayed by ELISA. The fold change was calculated relative to IL1B-stimulated siCONT-transfected cells. All data are displayed as mean±S.E.M.*P<0.05 vs IL1B-stimulated siCONT-transfected cells (one-way ANOVA).
and knockdown of RAF1 was performed by siRNA. The efficacy of transfection was analysed by qRT-PCR and western blotting (Supplementary Figure S1, see section on supplementary data given at the end of this article). When compared to siCONT-transfected cells, siRAF1 transfection resulted in 80% decrease in RAF1 mRNA expression and 60% decrease in RAF1 protein expression. There was no effect of siRAF1 on cell viability as determined by MTT assay.

The next aim was to determine the importance of RAF1 in the expression of inflammation-induced pro-labour mediators. Thus, for all subsequent experiments, after labouring myometrium when compared to non-labouring samples (Fig. 1B).

Effect of pro-inflammatory cytokines on RAF1 expression in human myometrium

The pro-inflammatory cytokines IL1B and TNF have been shown to induce preterm birth in vivo (Sadowsky et al. 2006). Thus, the next aim was to determine the effect of IL1B or TNF on the expression of RAF1 in primary human myometrial cells. As shown in Fig. 1C, incubation of myometrial cells with IL1B or TNF significantly increased RAF1 protein expression.

Effect of siRAF1 on pro-inflammatory cytokines and chemokines in primary myometrium cells

Given that pro-inflammatory cytokines increase RAF1 expression in human myometrium, we next sought to determine if RAF1 regulates the formation of pro-inflammatory and pro-labour mediators induced by IL1B and TNF. For these studies, primary myometrial cells isolated from fresh myometrial tissue were used,

Figure 3 Effect of siRAF1 knockdown on TNF-induced pro-inflammatory cytokines and chemokines. Human primary myometrial cells were transfected with or without 200 nM siRAF1 or siCONT for 48 h and then treated with 10 ng/ml TNF for an additional 20 h (n=5 patients). (A, B, C and D) IL1A, IL1B, IL6, CXCL8 and CCL2 mRNA abundance was analysed by qRT-PCR and the fold change was calculated relative to TNF-stimulated siCONT-transfected cells. (E, G and H) IL6, CXCL8 and CCL2 concentration in the incubation medium was assayed by ELISA. The fold change was calculated relative to TNF-stimulated siCONT-transfected cells. All data are displayed as mean±s.e.m. *P<0.05 vs TNF-stimulated siCONT-transfected cells (one-way ANOVA).

Figure 4 Effect of siRAF1 knockdown on the PTGS2-prostaglandin pathway. Human primary myometrial cells were transfected with or without 200 nM siRAF1 or siCONT for 48 h and then treated with (A, B and C) 1 ng/ml IL1B or (D, E and F) 10 ng/ml TNF for an additional 20 h (n=5 patients). (A, B and D) PTGS1 and PTGS2 mRNA abundance was analysed by qRT-PCR and the fold change was calculated relative to IL1B- or TNF-stimulated siCONT-transfected cells. (C and F) PGF2α concentration in the incubation medium was assayed by ELISA, and the fold change was calculated relative to IL1B- or TNF-stimulated siCONT-transfected cells. All data are displayed as mean±s.e.m. *P<0.05 vs IL1B-stimulated siCONT-transfected cells (one-way ANOVA); **P<0.05 vs TNF-stimulated siCONT-transfected cells (one-way ANOVA).
Silencing of RAF1 represses NF-κB p65 transcriptional activity

In non-gestational tissues, RAF1 has been shown to regulate inflammation via the pro-inflammatory transcription factor NF-κB (Nakano et al. 2000, Baumann et al. 2003, Lappas & Rice 2004, Edelblum et al. 2008a,b, Lu et al. 2010). Thus, to determine whether NF-κB is involved in the RAF1 pathway, the effect of siRAF1 on NF-κB transcriptional activity was determined. As expected, treatment with IL1B (Fig. 5A) and TNF (Fig. 5B) significantly increased NF-κB p65 luciferase activity in siCONT-transfected myometrial cells. The effect of transfection with siRAF1 was a significant decrease in IL1B- and TNF-induced luciferase activity.

Silencing of RAF1 inhibits ERK activation in the presence of IL1B but not TNF

RAF1 activation initiates an MAPK cascade that leads to the phosphorylation and activation of MAPK1. Thus, we next explored the effect of siRAF1 on activation of MAPK1 by assessing phosphorylation of MAPK1 by western blotting. As shown in Fig. 6A, IL1B-induced

Figure 6  Effect of siRAF1 knockdown on MAPK1 activation. Human primary myometrial cells were transfected with or without 200 nM siRAF1 or siCONT for 48 h and then treated with (A) 1 ng/ml IL1B or (B) 10 ng/ml TNF for an additional 2 h (n=5 patients). Activated MAPK1 (p-MAPK1) protein expression was assessed by Western blotting, normalised to total MAPK1 protein expression and the fold change was calculated relative to IL1B-stimulated siCONT-transfected cells. Data displayed as mean±S.E.M. *P<0.05 vs IL1B-stimulated siCONT-transfected cells (one-way ANOVA). Representative Western blot from one patient is also shown.
phosphorylation of MAPK1 was significantly attenuated in cells transfected with siRAF1. There was, however, no effect of TNF with or without siRAF1 on MAPK1 activation (Fig. 6B). These findings suggest that RAF1 may regulate IL1B-induced pro-labour mediators via activation of MAPK1 while RAF1 regulates TNF-induced pro-labour mediators via MAPK1-independent mechanisms. Thus, to confirm a role for RAF1 in the regulation of IL1B-stimulated pro-labour mediators, primary myometrial cells were incubated in the presence of IL1B with or without the specific MAPK1 inhibitor U0126. As shown in Fig. 7, treatment of myometrial cells with U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PGF2α mRNA abundance (Fig. 7A, B, C and D) and IL1B-induced IL6, CXCL8, CCL2 and PGF2α concentration in the incubation medium was assayed by ELISA. The fold change was calculated relative to IL1B. (E, F and H) IL6, CXCL8, CCL2 and PGF2α concentration in the incubation medium was assayed by ELISA. The fold change was calculated relative to IL1B. (E, F and H) IL6, CXCL8, CCL2 and PGF2α concentration in the incubation medium was assayed by ELISA. The fold change was calculated relative to IL1B. (I) Human myometrial cells were transfected with 0.75 ng NF-κB p65 luciferase activity induced by IL1B was significantly attenuated by treatment with U0126. 

**Figure 7** Effect of MAPK1 inhibitor U0126 on IL1B pro-labour mediators. Human primary myometrial cells were incubated in the absence or presence of 5 μM U0126 with or without 1 ng/ml IL1B for 20 h (n=5 patients). (A, B, C and D) IL6, CXCL8, CCL2 and PTGS2 mRNA abundance was analysed by qRT-PCR and the fold change was calculated relative to IL1B. (E, F and H) IL6, CXCL8, CCL2 and PGF2α concentration in the incubation medium was assayed by ELISA. The fold change was calculated relative to IL1B. (I) Human myometrial cells were transfected with 0.75 ng NF-κB reporter construct. After 48 h, cells were treated with 1 ng/ml IL1B for an additional 20 h (n=5 patients). Promoter activity (normalised with Renilla expression) is expressed as a ratio of luciferase activity of IL1B. All data are displayed as mean±S.E.M. *P<0.05 vs IL1B (one-way ANOVA).

Discussion

In this study, it is reported, for the first time, that RAF1 is increased in labouring myometrium and in response to the pro-inflammatory cytokines IL1B and TNF. Further, a novel role for RAF1 in the genesis of pro-labour mediators, induced by inflammation, is also demonstrated. Specifically, IL1B induces the expression and secretion of pro-inflammatory cytokines and chemokines, PTGS2 expression and prostaglandin secretion in primary myometrial cells through the RAF1–MAPK1–NF-κB signalling pathway. TNF, on the other hand, induces the expression and secretion of pro-inflammatory cytokines and chemokines, PTGS2 expression and prostaglandin release through the RAF1–NF-κB signalling pathway via an MAPK1-independent mechanism. Aberrant RAF1 expression may thus establish an autocrine loop, which results in the continuous stimulation of inflammation.

Human term labour is a sterile inflammatory process (Christiaens et al. 2008). Activation of maternal immune system leads to a massive influx of leukocytes in the uterus and myometrium through the release of chemokines such as CXCL8 and CCL2 (Thomson et al. 1999). Infiltrating leukocytes augments the pro-inflammatory microenvironment through the release pro-inflammatory cytokines to amplify or initiate the process of parturition. Thus, increased RAF1 expression in human term labouring myometrium suggests that it may be a consequence of this increased inflammation. In support, treatment of human primary myometrial cells with the pro-inflammatory cytokines IL1B or TNF significantly increased RAF1 expression.

IL1B, which is released from infiltrating leukocytes in the uterus and myometrium, is a key pro-inflammatory cytokine involved in human parturition. Human labour is associated with increased concentrations of IL1B in both gestational tissues and biological fluids (Elliott, et al. 2001, Bowen et al. 2002, Tattersall et al. 2008), and intra-amniotic and/or systemic administration of IL1B to mice and monkeys induces preterm labour (Romero et al. 1991, Romero & Tartakovsky 1992, Sadowsky et al. 2006). IL1B is thought to contribute to the onset of labour by stimulating and potentiating uterine contractions. It induces basal and store-operated calcium entry in myometrial smooth muscle cells (Tribe et al. 2003), thus directly enhancing their contractile potential. IL1B can also increase the production of pro-inflammatory cytokines and chemokines; promote the production of prostaglandins via PTGS2, mediators of uterine contractions; and matrix metalloproteinases (MMPs) which activate cervical ripening and foetal membrane rupture, events culminating in successful labour and delivery (Roh et al. 2000, Bowen et al. 2002, Keelan et al. 2003, Lappas & Rice 2004, Christiaens et al. 2008, Tattersall, et al. 2008). The findings of this study demonstrate that RAF1 is involved in the genesis of pro-inflammatory and
pro-inflammatory cytokine IL6 and the chemokines CXCL8 and CCL2. In expression and secretion of the pro-inflammatory cytokine IL6 and the chemokines CXCL8 and CCL2. In addition, IL1B-induced mRNA expression and subsequent prostaglandin PGF2α release.

TNF is another pro-inflammatory cytokine that plays a central role in the terminal effector pathways of human labour and deliver. TNF can amplify or initiate the process of parturition by further increasing cytokine production, increasing PTGS2-mediated prostaglandin synthesis and activating MMPs (Roh et al. 2000, Bowen et al. 2002, Keelan et al. 2003, Lappas & Rice 2004, Christiaens et al. 2008, Tattersall et al. 2008). In addition, TNF can induce preterm labour in animal models (Sadowsky et al. 2006). Thus, it was also of interest to determine if RAF1 also regulates pro-inflammatory and pro-labour mediators in the presence of TNF. Human primary myometrial cells transfected with siRAF1 released significantly less IL6, CXCL8 and CCL2 when stimulated with TNF. siRAF1-transfected cells also displayed decreased TNF-induced PTGS2 mRNA expression and prostaglandin PGF2α release. Collectively, this data indicate that RAF1 is important to TNF signalling pathways associated with preterm birth.

Activation of RAF1 initiates a cascade of events that eventually leads to the activation of MAPK1 (Alessi et al. 1994). Activated MAPK1 has been shown to regulate a number of cellular functions, including inflammation (Kyriakis & Avruch 1996). Likewise, we have previously shown that MAPK1 regulates LPS-stimulated release of pro-inflammatory cytokines and prostaglandins from human placenta and foetal membranes (Lappas et al. 2007). Furthermore, MAPK1 is involved in IL1B-induced matrix metallopeptidase 9 (MMP9) mRNA expression and pro-MMP9 in human primary amnion cells (Lappas et al. 2011). In this study, knockdown of RAF1 was associated with decreased activation of MAPK1 in the presence of IL1B but not TNF. These findings suggest that, in human myometrium, TNF activates RAF1 to induce the expression of pro-inflammatory and pro-labour labour mediators independently of MAPK1. On the other hand, MAPK1 is required for RAF1-mediated inflammation in the presence of IL1B. Thus, the MAPK1 inhibitor U0126 was used to determine if MAPK1 regulates IL1B-induced expression of pro-inflammatory and pro-labour mediators in human myometrium. Indeed, incubation of primary myometrial cells with U0126 significantly decreased IL1B-induced mRNA expression and secretion of the pro-inflammatory cytokine IL6 and the chemokines CXCL8 and CCL2. In addition, IL1B-induced PTGS2 mRNA expression and PGF2α secretion was also significantly suppressed by U0126. Collectively, these findings suggest that RAF1 signals through MAPK1 to regulate IL1B-induced pro-inflammatory and pro-labour mediators in human myometrium.

Another candidate for a RAF1 effector is NF-κB, a transcription factor central to the regulation of the terminal effector pathways of human labour and delivery (Lappas et al. 2002, 2003, Lindstrom & Bennett 2005, Lappas & Rice 2007). NF-κB is sequestered in the cytosol by its inhibitor protein (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; NFKBIA), which upon activation is phosphorylated and targeted for degradation (Karin & Delhase 2000). In this study, knockdown of RAF1 in primary myometrial cells was associated with decreased IL1B- and TNF-induced NF-κB activation. These findings suggest that IL1B and TNF may regulate pro-labour mediators via RAF1 activation of NF-κB. These studies provide a novel functional linkage between pro-inflammatory cytokines and NF-κB signalling, two key players involved in inflammation-driven preterm birth.

Both MAPK1-dependent and -independent mechanisms may be involved in RAF1 activation of NF-κB. The MAPK1 substrate p90-RSK can phosphorylate NFKBIA and induce its degradation (Ghoda et al. 1997). In addition, MAPK1 can down-regulate the expression of PAR4, an inhibitor of NF-κB activation (Barradas et al. 1999). An emerging theme is that RAF1 induces NFKBIA degradation via MEK1 (MEK kinase 1) independently of MAPK1 (Baumann et al. 2000). For example, RAF1 promotes colon epithelial cell survival through NF-κB downstream of TNF receptor 1 (TNFR1) activation independently of MAPK1 (Edelblum et al. 2008a). In this study, IL1B-induced NF-κB activation is dependent on MAPK1. That is, the MAPK1 inhibitor U0126 significantly attenuated IL1B-induced NF-κB transcriptional activity. Taken together, these findings suggest that IL1B-induced RAF1 activation of NF-κB is dependent on MAPK1.

Collectively, the findings of this study suggest that in human myometrium, IL1B induces the expression of pro-inflammatory and pro-labour mediators via a RAF1–MAPK1–NF-κB-dependent pathway. On the other hand, TNF induces the expression of pro-labour mediators via RAF1–NF-κB, which was independent of MAPK1. Regulation of RAF1 may constitute a useful therapeutic target for inflammation-induced preterm birth.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/REP-15-0607.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
Associate Professor Martha Lappas was supported by a Career Development Fellowship from the National Health and Medical Research Council (NHMRC; grant no. 1047025). Additional funding was provided by the Normal Beischer Medical Research Foundation and the Mercy Research Foundation.

Acknowledgements
The following are gratefully acknowledged: Ratana Lim and Gillian Barker (Obstetrics, Nutrition and Endocrinology Group, Department of Obstetrics and Gynaecology, University of Melbourne) for their excellent technical assistance; the Clinical Research Midwives Genevieve Christophers, Gabrielle Pell and Rachel Murdoch for sample collection; and the Obstetrics and Midwifery staff of the Mercy Hospital for Women for their co-operation.

References
Lim R, Barker G & Lappas M 2014 TREM-1 expression is increased in human placentas from severe early-onset preeclamptic pregnancies where it may be involved in syncytialization. Reproductive Sciences 21 562–572. (doi:10.1177/1933719113503406)

www.reproduction-online.org

Reproduction (2016) 151 411–420

Downloaded from bioscientifica.com at 12/21/2018 04:58:43AM via free access


Mebratu Y & Tesfaigzi Y 2009 How ERK1/2 activation controls cell proliferation and cell death is subcellular localization the answer? Cell Cycle 8 1168–1175. (doi:10.4161/cc.8.8.8147)


Received 21 December 2015
First decision 8 January 2016
Revised manuscript received 18 January 2016
Accepted 25 January 2016